← Leaderboards
Abigail Benkert
Duke University
$159,684
Attributed
$159,684
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $83.4K · FY2023–24$100K$75K$50K$25K$0
'23
'24
Funding mix
By agency
NIH$159,684 · 1
By mechanism
F32$159,684 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Jen-Tsan Ashley Chi$7,491,502
- Aravind Asokan$26,081,479
- Gregory E Crawford$24,798,952
- Charles A Gersbach$24,146,412
- Joseph Heitman$44,576,851
Others in their field
Other Rising Stars on “Affect”
- Daniel Hunter Reirden · Westat, Inc.$15,038,020
- Thomas K Karikari · Wake Forest University Health Sciences$14,340,584
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Brian Todd Schaneberg · Illinois Institute Of Technology$13,469,813
- Benjamin M Greenberg · Ut Southwestern Medical Center$11,474,975
- Eric Anderson · Columbia University Health Sciences$11,474,975
Research focus
AffectAutosomeBase PairingBiochemicalCardiac MyocytesCardiomyopathiesCareerCell LineCell ModelCellsCodon NucleotidesCohortComplementary DnaDelivery VehicleDisease PhenotypeDisease ProgressionEfficacy EvaluationEvaluationExertionExperimental StudyFamilyFellowshipFoundationsAdrenergic Agents
Grant awards (2)
Evaluation of adeno-associated viral (AAV) mediated gene replacement therapy as a therapeutic option for SLC25A4 deficiency$83,392
F32 · FY2024 · HL · contact PI
Evaluation of adeno-associated viral (AAV) mediated gene replacement therapy as a therapeutic option for SLC25A4 deficiency$76,292
F32 · FY2023 · HL · contact PI